Skip to content
nelivaptan

Structure via PubChem · Public domain (PubChem)

EntityQ6989992· pop 5· linked from 64 articles

nelivaptan

Sign in to save

Also known as SSR-149,415, SSR149415

Nelivaptan (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.

In the Vinony graph

Within Vinony's link graph, nelivaptan is referenced by 64 other articles, and connects out to arginine vasopressin, oral administration and World Health Organization.

Vinony files it under Abandoned drugs, Chemical pages without DrugBank identifier and Drugboxes which contain changes to verified fields.

Its subject is documented across 5 Wikipedia language editions.

Chemical data

Formula
C30H32ClN3O8S
Molecular weight
630.1 g/mol
IUPAC name
(2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
SMILES
CN(C)C(=O)[C@@H]1C[C@H](CN1[C@]2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
InChIKey
NJXZWIIMWNEOGJ-WEWKHQNJSA-N
XLogP
3.4
Polar surface area
134 Ų
H-bond donors
1
H-bond acceptors
9
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 2
Molecule type
Small molecule
Indications
anxiety, depressive disorder

via ChEMBL · EBI

Wikidata facts

Mass
629.16
Show 3 more facts
chemical formula
C₃₀H₃₂ClN₃O₈S
isomeric SMILES
CN(C)C(=O)[C@@H]1C[C@H](CN1[C@]2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
canonical SMILES
CN(C)C(=O)C1CC(CN1C2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

3 sections
Contents
  • See also
  • References
  • External links

Nelivaptan (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.

==See also== ABT-436 Balovaptan SRX-246 TS-121

Excerpted from Wikipedia’s “nelivaptan” article, available under the CC BY-SA 4.0 licence.

Available in 5 languages

via Wikidata sitelinks · CC0

Connections

Categories